- Home
- CMRE vs ETNB Comparison
CMRE vs ETNB Comparison
Compare CMRE & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRE
- ETNB
- Stock Information
- Founded
- CMRE 1974
- ETNB 2018
- Country
- CMRE Monaco
- ETNB United States
- Employees
- CMRE N/A
- ETNB N/A
- Industry
- CMRE Marine Transportation
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- CMRE Consumer Discretionary
- ETNB Health Care
- Exchange
- CMRE Nasdaq
- ETNB Nasdaq
- Market Cap
- CMRE 1.3B
- ETNB 1.5B
- IPO Year
- CMRE 2010
- ETNB 2019
- Fundamental
- Price
- CMRE $11.57
- ETNB $9.43
- Analyst Decision
- CMRE Hold
- ETNB Strong Buy
- Analyst Count
- CMRE 1
- ETNB 9
- Target Price
- CMRE $13.00
- ETNB $26.63
- AVG Volume (30 Days)
- CMRE 560.4K
- ETNB 1.5M
- Earning Date
- CMRE 07-31-2025
- ETNB 08-07-2025
- Dividend Yield
- CMRE 3.98%
- ETNB N/A
- EPS Growth
- CMRE N/A
- ETNB N/A
- EPS
- CMRE 2.37
- ETNB N/A
- Revenue
- CMRE $2,085,912,000.00
- ETNB N/A
- Revenue This Year
- CMRE N/A
- ETNB N/A
- Revenue Next Year
- CMRE N/A
- ETNB N/A
- P/E Ratio
- CMRE $4.46
- ETNB N/A
- Revenue Growth
- CMRE 56.37
- ETNB N/A
- 52 Week Low
- CMRE $6.02
- ETNB $4.16
- 52 Week High
- CMRE $11.89
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- CMRE 69.15
- ETNB 49.00
- Support Level
- CMRE $11.64
- ETNB $9.07
- Resistance Level
- CMRE $11.89
- ETNB $9.62
- Average True Range (ATR)
- CMRE 0.27
- ETNB 0.40
- MACD
- CMRE 0.02
- ETNB 0.05
- Stochastic Oscillator
- CMRE 84.40
- ETNB 69.49
About CMRE Costamare Inc. $0.0001 par value
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).